BioFortis (United States)

Gastrointestinal (GI) disorders are a frequent concern for pet owners and veterinarians. Dietary management of mild GI disorders is often essential in order to correct imbalances in the gut flora. In this context, “biotics,” including probiotics, prebiotics, and postbiotics, have received increasing attention for their potential to favorably modulate the gut microbiota and support digestive function. In this study, we investigated the effect of a nutritional supplement containing a specific blend of prebiotics (baobab fruit pulp and acacia gum) and postbiotics (inactivated L. helveticus and selected yeast fractions) on digestive signs exhibited by healthy dogs and cats with mild GI imbalances, such as soft stools, increased quantity of stools or flatulence. The supplement was tested over a 28-day period. Digestive signs were evaluated on 57 dogs and 57 cats and the microbiota analysis was conducted on samples from 35 dogs and 27 cats. Questionnaires completed by the pet owners at regular intervals were used to evaluate digestive signs, while changes in the intestinal microbiota were assessed by fecal sample analysis performed before and after supplementation. The supplement was accepted either alone or mixed with food by 94% of dogs and 91% of cats. In both cats and dogs, the supplementation significantly improved digestive health as of day 7 (p < 0.001). Animals starting the study with impaired stool consistency or high quantity of stools showed significant improvement by day 7. The stool odor also improved from the first week. The proportion of dogs and cats with flatulence was reduced by 45 and 63%, respectively, by day 28 (p < 0.001), and the proportion of pets vomiting was reduced by 51 and 54%, respectively (p < 0.001). The impact on gut microbiota involved mainly changes on multiple subdominant taxa (such as Megamonas and Peptacetobacter in dogs, Anaerotignum and Succinivibrio in cats), without altering the overall microbial community architecture (as shown by diversity indices). Altogether, these results show that the supplement tested (Floragest™ soft chews, Virbac) can help support the digestive health of dogs and cats with mild gastrointestinal disorders.

近年来,对益生元和益生菌作用机制的科学认识有了很大的发展。虽然保健功效往往来自菌株及其产品的特异性,但一些益生元和益生 菌的保健作用可能是由它们的互作机制驱动的,并且可能是可遗传的。在多学科研究环境中使用新兴的生理学和分析工具将有助于进一步 阐明其作用机制。通过这种方式,将有可能提高对人们对益生元、益生菌和合生元保健作用的理解。本简版专论的编写基于最新的科学证据,是一本有价值的参考书, 旨在向广大读者介绍肠道微生物群以及益生元和益生菌的健康概念。

To examine changes in weight and related outcomes in response to a commercial weight loss program compared to a self-directed diet in adults with overweight or obesity. Participants were randomly assigned [stratified by body mass index (BMI) and age] to a commercial weight loss program (n = 38) or to a self-directed Dietary Approaches to Stop Hypertension (DASH) diet (n = 40) for a 16-week period. Daily energy intake goals were 1,500 kcal/d for men and 1,200 kcal/d for women, except for the first week of the commercial program (1,000 kcal/d). This study was registered at http://ClinicalTrials.gov (NCT03017443). Primarily Caucasian (71%) women (n = 61) and men (n = 17) from the greater metropolitan area of the city of Chicago, IL, USA. with a mean baseline BMI of 34.4 kg/m2, body weight of 95.7 kg, and age of 50.4 years. Data = mean (95% CI). At week 16, the commercial program group lost significantly more body weight [-5.9 (-7.5, -4.3) kg vs. -1.8 (-2.9, -0.8) kg; or -6.4 vs. -1.8% of initial body weight, respectively], fat mass [-4.4 (-5.7, -3.1) kg vs. -1.2 (-2.1, -0.4) kg] and total body circumference (chest + waist + hip + upper arm + thigh) [-16.9 (-21.5, -12.3) cm vs. -5.8 (-9.0, -2.6) cm] (p < 0.01 for all). Additionally, more participants in the commercial program group lost a clinically meaningful amount of weight, defined as ≥5% of initial body weight, at week 16 (58% vs. 13%, p < 0.001). The commercial program resulted in greater weight loss and improvements in body composition/anthropometric parameters compared to a self-directed DASH diet over a 16-week period. Some important limitations were that no objective measurements of dietary intake or physical activity were collected to potentially ascertain the independent or combined effects of these components on weight loss (or lack thereof). Additionally, future research is warranted in order to understand the effects of this program, and similar programs, on longer term changes in body weight, in particular weight loss maintenance, as weight regain is common following the cessation of a structured weight loss intervention.

The therapeutic value of many drugs can be limited by gastrointestinal (GI) adverse effects such as nausea and vomiting. Nausea is a subjective human sensation, hence little is known about preclinical biomarkers that may accurately and effectively predict its presence in man. The aim of this analysis was to use informatics and data-mining tools to identify plausible preclinical GI effects that may be associated with nausea and that could be of potential use in its prediction. A total of 86 marketed drugs were used in this analysis, and the main outcome was a confirmation that nausogenic and non-nausogenic drugs can be clearly separated based on their preclinical GI observations. Specifically, combinations of common preclinical GI effects (vomiting, diarrhea, and salivary hypersecretion) proved to be strong predictors. The model was subsequently validated with a subset of 20 blinded proprietary small molecules and successfully predicted clinical outcome in 90% of cases. This investigation demonstrated the feasibility of data-mining approaches to facilitate discovery of novel, plausible associations that can be used to understand drug-induced adverse effects.